News Sentiment

NUVB sentiment intelligence

Nuvation Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 66 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.81 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+1.9% over one week, +18.1% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Nuvation Bio’s Global Strategy

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction 1.9% Price digesting
Trend fit Trend inactive 18.1% over four weeks
Fair value 83.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 44
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 9
simplywall.st 8
Investing.com 7
TradingView 4
MT Newswires 3
PR Newswire 3
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 20
Regulatory and legal 4
Analyst action 3
Deals and strategy 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 66
Investing.com Direct company coverage

Nuvation Bio director Robert Mashal buys $118,250 in stock

Robert Mashal, a director at Nuvation Bio Inc. (NASDAQ:NUVB), recently purchased 25,000 shares of the company’s Class A Common Stock for $118,250 through his revocable trust. This transaction increases his indirect ownership to 225,000 shares. The purchase comes as InvestingPro a

Tone
Positive 70/100
Event
Market update
Published
12 Jun 2026 00:39
Source
Investing.com
Stock Titan Direct company coverage

Nuvation Bio (NUVB) director’s trust buys 25,000 Class A shares

Nuvation Bio director Robert Mashal, through his revocable trust, purchased 25,000 shares of Class A Common Stock at $4.73 per share in an open-market transaction. This acquisition increases the trust's total holdings to 225,000 shares of Nuvation Bio Class A Common Stock. The tr

Tone
Positive 74/100
Event
Deals and strategy
Published
11 Jun 2026 23:39
Source
Stock Titan
Stock Titan Direct company coverage

Nuvation Bio (NUVB) shareholders elect directors, ratify KPMG and approve pay

Nuvation Bio Inc. (NUVB) announced the results of its 2026 Annual Meeting. Shareholders elected Class A directors Robert B. Bazemore, Jr. and Robert Mashal, M.D., and Class B director Kim Blickenstaff, to serve until the 2029 annual meeting. Additionally, KPMG LLP was ratified as

Tone
Neutral 50/100
Event
Earnings
Published
28 May 2026 14:39
Source
Stock Titan
Minichart Direct company coverage

Nuvation Bio Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results

Nuvation Bio Inc. filed an 8-K form with the SEC, detailing the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Key outcomes included the election of directors, ratification of KPMG LLP as auditor, and an advisory vote on executive compensation. The repor

Tone
Neutral 50/100
Event
Earnings
Published
28 May 2026 11:40
Source
Minichart
Stock Titan Direct company coverage

Nuvation Bio Inc. (NUVB) director awarded 76,923 stock options in corrected filing

Nuvation Bio Inc. director Xiangmin Cui's insider trading report has been corrected through an amended Form 4 filing, revealing he was granted 76,923 stock options for Class A common stock on February 27, 2026. This rectifies an administrative error in a previous filing that repo

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 00:10
Source
Stock Titan
Stock Titan Direct company coverage

Nuvation Bio (NUVB) director Cui receives 123,397 stock options expiring 2036

Nuvation Bio (NUVB) director Xiangmin Cui was granted 123,397 stock options with an exercise price of $4.79 per share, expiring on May 20, 2036. These options represent a compensation-related acquisition and will fully vest on the earlier of May 21, 2026, or the next shareholder

Tone
Neutral 50/100
Event
Deals and strategy
Published
27 May 2026 00:10
Source
Stock Titan
Stock Titan Direct company coverage

Nuvation Bio (NUVB) director gets 123,397 stock options at $4.79

Nuvation Bio Inc. director Robert B. Bazemore was granted 123,397 stock options for Class A common stock with an exercise price of $4.79 per share, expiring on May 20, 2036. The options will vest 100% on May 21, 2026, or the next annual shareholder meeting, contingent on his cont

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 00:10
Source
Stock Titan
Stock Titan Direct company coverage

Director at Nuvation Bio (NASDAQ: NUVB) awarded 123,397 stock options

Robert Mashal, a director at Nuvation Bio (NASDAQ: NUVB), was granted 123,397 stock options with an exercise price of $4.79 per share. These options will vest 100% on the earlier of May 21, 2026, or the next shareholder annual meeting, provided he maintains continuous service. Th

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 00:10
Source
Stock Titan
PR Newswire Direct company coverage

Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting

Nuvation Bio will present new patient-reported outcomes data from the pivotal TRUST-II study of IBTROZI® (taletrectinib) at the ASCO 2026 Annual Meeting. The data shows that 88% of patients with ROS1-positive non-small cell lung cancer (NSCLC) reported improved or stable quality

Tone
Positive 74/100
Event
Market update
Published
25 May 2026 11:40
Source
PR Newswire
Quartr Direct company coverage

Nuvation Bio (NUVB) Proxy filing Summary

Nuvation Bio (NUVB) has scheduled its Annual Meeting for May 21, 2026, where stockholders will vote on electing three directors, ratifying KPMG LLP as the auditor for 2026, and an advisory vote on executive compensation. The board recommends voting in favor of all proposals. The

Tone
Neutral 50/100
Event
Market update
Published
18 May 2026 22:10
Source
Quartr
Simply Wall Street Direct company coverage

Nuvation Bio (NYSE:NUVB) - Stock Analysis

Nuvation Bio (NYSE:NUVB) is a clinical-stage biopharmaceutical company focused on cancer treatment. The company recently reported a surprise statutory profit in Q1 2026, exceeding analyst expectations, and its lead product candidate, IBTROZI (taletrectinib), has received FDA appr

Tone
Positive 62/100
Event
Earnings
Published
14 May 2026 20:15
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Results: Nuvation Bio Inc. Confounded Analyst Expectations With A Surprise Profit

Nuvation Bio Inc. (NYSE: NUVB) shares rose 8.1% after reporting a surprise profit of US$0.01 per share and revenues of US$83m for the first quarter, significantly exceeding analyst expectations. Analysts have increased their price target to US$12.33 and reduced their loss per sha

Tone
Positive 65/100
Event
Earnings
Published
13 May 2026 00:10
Source
Simply Wall Street